Beyond the Account: How ABM Uncovers Buying Committees and Why That’s Key in B2B Sales

The shift from lead-based marketing to account-based marketing was a meaningful evolution. Instead of chasing individual contacts and hoping the right person would eventually surface, ABM focused commercial resources on a defined set of high-value organizations, and measured success at the account level rather than the lead level.

But account-level thinking alone is not the complete picture. An account is not a buyer. A buying committee is.

The most sophisticated B2B marketing programs have taken a further step: targeting not just accounts, but the specific groups of individuals within those accounts who are collectively responsible for a purchase decision. Understanding who those people are, what each of them needs to see before they will advocate for your solution, and how to reach all of them simultaneously is what separates ABM programs that generate real pipeline from those that generate account-level engagement without commercial traction.

This post explains the buying committee reality in B2B life sciences, how ABM can be used to surface and engage every relevant stakeholder, and how the pattern of engagement across a buying group becomes one of the most valuable signals in the entire commercial program.

Why Targeting Accounts Is Necessary but Not Sufficient

When a B2B life science company runs an ABM campaign targeting a specific biotech account, it typically generates engagement from some individuals at that company. An ad gets clicked. A white paper gets downloaded. A webinar registration comes in. These are positive signals, but on their own they tell an incomplete story.

The critical question is not just whether someone at the account is engaging. It is whether the right people at the account are engaging, and whether enough of them are engaging simultaneously to indicate that a purchase decision is being considered.

In most B2B life science purchases, a single engaged contact is rarely sufficient to move a deal forward. The purchasing process involves multiple stakeholders, each with a distinct perspective and a distinct set of concerns. A scientist who loves your technology cannot unilaterally approve a contract. A procurement manager who sees your pricing as competitive cannot evaluate your technical capabilities. Each member of the buying committee holds a piece of the decision, and failing to engage all of them means the deal can stall or die even when the initial interest is genuine.

This is the gap that committee-level targeting is designed to close.

The Anatomy of a Life Science Buying Committee

Buying committees in B2B life sciences vary by organization size, outsourcing model, and the nature of what is being purchased. But most purchase decisions of meaningful size involve some combination of the following personas:

The Scientific End-User: the researcher, scientist, or clinical specialist who will actually use the solution. This person cares primarily about technical performance, methodological fit, and whether the solution will work for their specific application. Their endorsement is typically a prerequisite for any serious vendor evaluation.

The Program or Project Lead: the Clinical Program Director, Principal Investigator, or Head of Development for the specific program driving the purchasing need. This person cares about timelines, deliverables, and whether the vendor can reliably execute against the program milestones. They often function as the internal champion if the scientific case is strong.

The Procurement or Vendor Management Function: responsible for vendor qualification, contract terms, pricing, and compliance with the organization's purchasing policies. This persona is often invisible in early-stage engagement and becomes critical (and potentially obstructive) later in the process if not engaged proactively.

The Finance or Budget Holder: particularly relevant for larger contracts or early-stage biotechs where capital allocation decisions are made at a senior level. For mid-size and large biotech pharma, the budget approval process may be separated from the technical selection process.

The Legal and Regulatory Function: for purchases with regulatory or IP implications (which is a large proportion of life science vendor relationships), legal and regulatory affairs team members may need to review and approve vendor agreements.

The C-Suite or Senior Leadership: for strategic vendor relationships, preferred provider agreements, or contracts representing a significant portion of the organization's budget, executive-level buy-in is often required. Even when executives are not part of the day-to-day evaluation, their awareness and support is frequently necessary to close a deal.

The practical implication is that a marketing program focused exclusively on the scientific end-user — the most natural audience for technically-oriented content marketing — is engaging only one member of a committee that may include five or more distinct decision-makers. ABM creates the framework to reach all of them.

How ABM Surfaces the Buying Committee

Identifying who is on the buying committee at a specific target account requires both proactive list-building and reactive signal-reading.

Proactive persona mapping starts with your ICP and the buying committee profiles documented for each ICP segment. For a given account, the commercial team uses contact databases and LinkedIn to identify the individuals at that company who hold the titles and roles corresponding to each buying committee persona. These individuals become the named contacts in the contact-level targeting list for that account: the specific people to whom ads will be served, SDR outreach will be directed, and webinar invitations will be sent.

Reactive signal-reading is equally important. Not every buying committee member will be visible in advance. Some are identified only when they begin engaging with campaign content. This could be someone new downloading a gated white paper, a different persona registering for a webinar, an unfamiliar name clicking through from a LinkedIn ad. Each new engagement from a previously unknown contact at a target account is a data point that refines and expands the picture of who the buying committee may include.

Contact-level ABM platforms like Influ2 and Propensity are enable contact-level targeting and individual-level visibility. Rather than knowing only that someone at a target account engaged, marketers can see precisely which person engaged, with what content, and how many times. When three individuals with different titles — a Biomarker Scientist, a Clinical Program Director, and a Procurement Manager — from the same mid-size biotech all interact with relevant content within a two-week window, this is a strong indication of possible  buying-committee level interest. That account should be flagged for targeted sales outreach and possibly receive increased marketing attention.

Deploying Content That Speaks to Each Persona

Identifying the buying committee is a key step, and one which is enabled by tailored content. Engaging each member of a buying committee effectively requires content and messaging calibrated to each persona's specific concerns, not a single piece of content served to everyone.

This is where the content matrix becomes an essential planning tool. A content matrix maps each buying committee persona to the content types and messages most likely to resonate with them at each stage of the funnel. What it produces in practice is a set of parallel tracks, each targeting a different member of the committee with content relevant to their role, that together build consensus across the full group.

For the scientific end-user, the most effective content is technically substantive: application notes, analytical validation data, peer-reviewed publications, detailed methodology comparisons. This audience wants to see evidence that the solution works and that the team behind it understands the science.

For the program lead, the relevant content shifts toward execution and outcomes: case studies documenting successful program delivery, data on timelines met and milestones achieved, testimonials from peers who have navigated similar program challenges. They need to be confident that the vendor will deliver.

For procurement and finance, the relevant content addresses risk management, vendor qualification, and commercial terms: quality system documentation, regulatory compliance credentials, contract flexibility, pricing transparency, and reference client information.

For senior leadership, the appropriate content is strategic: thought leadership on sector trends, evidence of the vendor's market position and reputation, and any data that positions the relationship as strategically valuable rather than merely transactional.

Running these parallel content tracks through ABM channels — LinkedIn ads targeted by title, contact-level ads to named individuals, email sequences to CRM contacts — means that it's much more likely that most members of the targeted buying committee are receiving relevant, role-specific content. This is how consensus is built before the formal vendor evaluation even begins.

A Content Matrix with Examples of Relevant Content by Persona and Engagement Stage

The Pattern of Engagement Is the Signal

The ultimate value of committee-level targeting in ABM is not just that it reaches more people at a target account. It is that the pattern of who is engaging, with what content, and over what timeframe, becomes a reliable indicator of purchase intent.

A single engaged contact might represent genuine interest or it might represent a researcher doing background reading with no near-term purchasing intent. But when engagement begins to appear across multiple personas at the same account, spanning scientific, operational, and commercial functions, the probability that a buying group is actively evaluating rises considerably. The breadth of engagement is the signal.

This is why committee-level visibility changes the nature of the marketing and sales handoff. Instead of passing individual leads to the SDR team and leaving them to figure out whether a deal opportunity exists, a well-instrumented ABM program hands off a picture of the buying committee: which specific individuals have engaged, with which content, and how their engagement maps to the personas typically present when a deal closes. That intelligence turns a cold outreach sequence into a precisely targeted, contextually informed commercial conversation.

The Bottom Line

Targeting accounts is necessary. Targeting buying committees is what makes ABM commercially productive.

The investment required to get there — persona mapping, contact-level targeting infrastructure, parallel content tracks by persona, and the organizational discipline to act on engagement signals quickly — is not trivial. But it is what separates ABM programs that generate genuine pipeline from those that generate engagement data with no clear path to revenue.

In B2B life sciences, where purchasing decisions involve multiple stakeholders and carry real consequences for the programs that depend on them, the ability to surround the full buying committee with relevant, credible, role-specific content before the evaluation formally begins is one of the most durable competitive advantages available.

‍